SCHEMBL4024359

SCHEMBL4024359

CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C.O=C(c1ccc(F)cc1)C(O)c1ccncc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 5/20 0.44
CES1 P23141 5/20 0.44
LTA4H P09960 1/20 0.42
ALDH1A1 P00352 3/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ADRB2 P07550 2/20 0.37
ADRB1 P08588 2/20 0.37
ADRB3 P13945 2/20 0.37
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
SLC6A9 P48067 1/20 0.36
PTGS2 P35354 1/20 0.35
KMT2A Q03164 2/20 0.34
POLB P06746 1/20 0.34
MEN1 O00255 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GAA P10253 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPK14 Q16539 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8821906 0.85 LTA4H (0.56) CES2CES1LTA4HALDH1A1LMNA
Hydrochloric Acid SCHEMBL11489832 0.83 LTA4H (0.55) CES2CES1LTA4HALDH1A1LMNA
SCHEMBL2660701 0.81 LTA4H (0.43) LTA4HALDH1A1HSD17B10ADRB2ADRB1
SCHEMBL8110862 0.76 LTA4H (0.46) CES2CES1LTA4HHSD17B10KDM4E
SCHEMBL7355965 0.75 LTA4H (0.43) LTA4HALDH1A1ADRB2ADRB1ADRB3
SCHEMBL10373981 0.73 CES2 (0.57) CES2CES1LTA4HALDH1A1TSHR
SCHEMBL5444935 0.73 CES2 (0.63) CES2CES1ALDH1A1TSHRHSD17B10
SCHEMBL15680018 0.73 CES2 (0.63) CES2CES1ALDH1A1TSHRHSD17B10
SCHEMBL5856026 0.72 CYP1A2 (0.53) CES2CES1ALDH1A1LMNAKMT2A
SCHEMBL14168446 0.71 LTA4H (0.55) CES2CES1LTA4HHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0854870-B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2009-06-10 EP disclosed
US-6083949-A FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR MERCK & CO., INC. (US) 2000-07-04 US disclosed
EP-0854870-A4 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 1999-01-07 EP disclosed
EP-0854870-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY Merck & Co., Inc. (US) 1998-07-29 EP disclosed
US-5717100-A Substituted imidazoles having anti-cancer and cytokine inhibitory activity MERCK & CO., INC. (US) 1998-02-10 US disclosed
WO-1997012876-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO., INC. (US) 1997-04-10 WO disclosed